Recent Insider Transactions Derivative • Aug 19
CEO, President & Director exercised options and sold US$783k worth of stock On the 15th of August, Kim Kelderman exercised options to acquire 11k shares at no cost and sold these for an average price of US$72.40 per share. This trade did not impact their existing holding. For the year to June 2020, Kim's total compensation was 11% salary and 89% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Kim currently holds less than 1% of total shares outstanding. Company insiders have collectively sold US$11m more than they bought, via options and on-market transactions in the last 12 months. Declared Dividend • Aug 14
Fourth quarter dividend of US$0.08 announced Dividend of US$0.08 is the same as last year. Ex-date: 17th August 2026 Payment date: 28th August 2026 Dividend yield will be 0.4%, which is about the same as the industry average. Payout Ratios Payout ratio: 27%. Cash payout ratio: 19%. Announcement • Aug 13
Bio-Techne Corporation Announces Cash Dividend on Common Shares for the Quarter Ended June 30, 2026, Payable on August 28, 2026 Bio-Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended June 30, 2026. The quarterly dividend will be payable August 28, 2026, to all common shareholders of record on August 24, 2026. Future cash dividends will be considered by the Board of Directors on a quarterly basis. Reported Earnings • Aug 13
Full year 2026 earnings: EPS misses analyst expectations Full year 2026 results: EPS: US$1.17 (up from US$0.47 in FY 2025). Revenue: US$1.22b (flat on FY 2025). Net income: US$181.9m (up 148% from FY 2025). Profit margin: 15% (up from 6.0% in FY 2025). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 2.5%. Revenue is forecast to grow 7.8% p.a. on average during the next 3 years, compared to a 7.0% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings. Recent Insider Transactions Derivative • Jul 31
CEO, President & Director exercised options and sold US$702k worth of stock On the 28th of July, Kim Kelderman exercised 35.00k options at around US$47.60, then sold 29k of the shares acquired at an average of US$72.07 per share and kept the remainder. For the year to June 2020, Kim's total compensation was 11% salary and 89% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Kim currently holds less than 1% of total shares outstanding. Company insiders have collectively sold US$8.9m more than they bought, via options and on-market transactions in the last 12 months. Announcement • Jul 08
Bio-Techne Launches Expanded R&D Systems AI-Engineered Designer Protein Portfolio Bio-Techne Corporation announced the launch of new additions to its R&D Systems AI-Engineered Designer Protein portfolio, designed to improve reproducibility and performance across advanced cell culture and cell therapy development workflows. The R&D Systems AI-Engineered Designer Protein platform enables the design and creation of new protein-based solutions to help researchers overcome current variability and scalability challenges in advanced cell culture by improving the stability and activity of critical reagents. By improving protein performance characteristics such as heat stability, activity, and solubility, Bio-Techne helps researchers achieve consistent results and scalable workflows from discovery through therapeutic development. These improvements are critical as cell therapies and organoid systems move toward clinical and commercial scale, where minor variations in cell signaling inputs can significantly impact outcomes. These additions build on Bio-Techne's strategy to develop a comprehensive portfolio of next-generation signaling technologies, following an earlier expansion of the R&D Systems AI-Engineered Design Protein portfolio. Together, these innovations, including hyperactive cytokines, heat-stable growth factors, and signaling pathway agonists, support stem cell culture, organoid development, and regenerative medicine workflows by enabling more controlled, reproducible systems across the continuum from basic research through process development and scaled-up manufacturing. The newly launched proteins include: FGF-4 Heat Stable – Designed to support pluripotent stem cell maintenance, embryonic development research, and differentiation workflows requiring sustained growth factor activity. FGF-7 Heat Stable – Engineered to support epithelial and tissue regeneration workflows, including advanced 3D culture systems and organoid expansion that require sustained stability at elevated temperatures. FGF-8b Heat Stable – Optimized for developmental biology, organoid modeling, and regenerative medicine applications where precise morphogenic signaling is critical. IL-3 Heat Stable – Designed to support hematopoietic stem and progenitor cell expansion and differentiation across early-stage and lineage-committed cell populations requiring sustained cytokine stability in culture. IL-15 Hyperactive – Engineered to drive increased expansion of NK cells and T cells, supporting cell therapy workflows and immunotherapy research, where enhanced signaling strength and persistence are vital. The expansion of the AI-Engineered Designer Protein portfolio reinforces Bio-Techne's leadership in developing high-performance signaling molecules for advanced biological systems. These innovations support organoid culture, stem cell differentiation, and cell therapy manufacturing; areas where reproducible scale-up from discovery to production is increasingly a requirement for success. Live News • Jun 27
Merck KGaA Announces $11.3 Billion Bio-Techne Acquisition Targeting Early 2027 Completion Merck KGaA has agreed to acquire Bio-Techne in an all-cash transaction valued between $11.3 billion and $11.5 billion, a deal that carries a roughly 36% premium to Bio-Techne’s recent trading price and has been unanimously approved by Bio-Techne’s board, pending regulatory approvals and a shareholder vote.
The acquisition is intended to fold Bio-Techne’s protein detection instruments and spatial biology diagnostic technologies into Merck’s broader life science portfolio, with both companies expecting operational synergies and an accretive effect on Merck’s earnings after completion, which is currently targeted for early 2027.
Bio-Techne’s share price is around $71.00, with the stock up 47.6% over the past 30 days, reflecting a sharp re-rating ahead of the proposed buyout.
The key question for shareholders is how the final transaction terms, timing and regulatory conditions compare with the current market price and whether any deal uncertainty or timeline slippage could affect the risk and return trade-off. Announcement • Jun 27
Merck KGaA (XTRA:MRK) entered into a definitive agreement to acquire Bio-Techne Corporation (NasdaqGS:TECH) for $11.5 billion. Merck KGaA (XTRA:MRK) entered into a definitive agreement to acquire Bio-Techne Corporation (NasdaqGS:TECH) for $11.5 billion on June 25, 2026. Merck KGaA will acquire Bio-Techne for $73 per share in cash, representing a total enterprise value of approximately $11.3 billion (€9.9 billion). The planned acquisition will be funded through a combination of existing cash on hand and proceeds from new debt.
The transaction is subject to approval of merger agreement by target board, approval by regulatory board / committee and approval of offer by target shareholders, subject to satisfaction of customary closing conditions. The proposed transaction has been approved by Bio-Techne's Board of Directors. The transaction is expected to close by late 2026 or early 2027. The proposed transaction is expected to be immediately accretive to EBITDA pre margin of both Life Science and the Group post-closing and EPS pre accretive by year 3 after closing. Cost synergies of approximately $159.6 million (€140 million) are expected to be fully realized by year 3 after closing.
Guggenheim Securities, LLC acted as financial advisor for Merck KGaA. J.P. Morgan Securities, Inc. acted as financial advisor for Merck KGaA. Sullivan & Cromwell LLP acted as legal advisor to Merck KGaA. Goldman Sachs & Co. LLC acted as financial advisor for Bio-Techne Corporation. Sidley Austin LLP acted as legal advisor for Bio-Techne Corporation. Price Target Changed • Jun 26
Price target increased by 10% to US$67.69 Up from US$61.31, the current price target is an average from 13 analysts. New target price is approximately in line with last closing price of US$71.00. The company is forecast to post earnings per share of US$1.17 for next year compared to US$0.47 last year. Buy Or Sell Opportunity • Jun 25
Now 39% overvalued after recent price rise Over the last 90 days, the stock has risen 39% to US$70.67. The fair value is estimated to be US$50.75, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 2.9% over the last 3 years. Earnings per share has declined by 43%. For the next 3 years, revenue is forecast to grow by 6.5% per annum. Earnings are also forecast to grow by 21% per annum over the same time period. Live News • Jun 16
Bio-Techne Shares Rise 4% as Activist Investor Urges Review of Company Options Bio-Techne shares moved higher after Ananym Capital Management disclosed a significant stake in the company.
The activist investor is urging Bio-Techne to conduct a broad review of its options, including a possible sale.
Ananym argues that exploring a transaction could provide more value to shareholders than the company remaining independent.
An activist campaign of this type often puts management under pressure to examine portfolio priorities, capital allocation and potential interest from buyers. This can lead to changes in how Bio-Techne is run or structured.
Investors may want to watch for any response from Bio-Techne’s board, including whether it forms a special committee, sets out a formal review process or rejects the call, as each path can carry different execution risks and timelines. Live News • Jun 06
Bio-Techne Unveils Integrated Four-Hour Workflow for Faster Bispecific and Biosimilar Analysis Bio-Techne and Refeyn announced a combined workflow that links charge and size characterization for bispecific antibodies and biosimilars.
The workflow connects Bio-Techne’s icIEF fractionation system with Refeyn’s mass photometry platform to correlate charge heterogeneity with molecular weight and aggregation at single-molecule resolution.
The integrated process is designed to run in roughly four hours and is aimed at reducing development risk and speeding up biosimilar manufacturing.
This collaboration points to a push by Bio-Techne to position its analytical tools more deeply in complex biologics workflows, especially where bispecifics and biosimilars require tighter quality characterization.
For investors, the key question is how widely this four-hour workflow will be adopted by biopharma customers and whether it can translate into higher demand for Bio-Techne’s analytical systems and related consumables, given the growing focus on efficiency and risk reduction in biologics development. Recent Insider Transactions Derivative • May 11
Executive VP of Finance & CFO exercised options and sold US$517k worth of stock On the 5th of May, James Hippel exercised 62.00k options at around US$47.60, then sold 57k of the shares acquired at an average of US$9.08 per share and kept the remainder. Since September 2025, James' direct individual holding has increased from 129.88k shares to 153.67k. Company insiders have collectively sold US$9.9m more than they bought, via options and on-market transactions in the last 12 months. Declared Dividend • May 11
Third quarter dividend of US$0.08 announced Dividend of US$0.08 is the same as last year. Ex-date: 18th May 2026 Payment date: 29th May 2026 Dividend yield will be 0.7%, which is higher than the industry average of 0.4%. Payout Ratios Payout ratio: 46%. Cash payout ratio: 19%. Price Target Changed • May 07
Price target decreased by 11% to US$64.55 Down from US$72.27, the current price target is an average from 11 analysts. New target price is 27% above last closing price of US$50.91. Stock is up 2.3% over the past year. The company is forecast to post earnings per share of US$1.20 for next year compared to US$0.47 last year. Announcement • May 07
Bio-Techne Corporation announces Quarterly dividend, payable on May 29, 2026 Bio-Techne Corporation announced Quarterly dividend of USD 0.0800 per share payable on May 29, 2026, ex-date on May 18, 2026 and record date on May 18, 2026. Reported Earnings • May 06
Third quarter 2026 earnings: EPS and revenues miss analyst expectations Third quarter 2026 results: EPS: US$0.33 (up from US$0.14 in 3Q 2025). Revenue: US$311.4m (down 1.5% from 3Q 2025). Net income: US$51.0m (up 126% from 3Q 2025). Profit margin: 16% (up from 7.1% in 3Q 2025). Revenue missed analyst estimates by 1.5%. Earnings per share (EPS) also missed analyst estimates by 12%. Revenue is forecast to grow 7.0% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 43% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings. Recent Insider Transactions Derivative • Apr 26
Executive VP of Finance & CFO exercised options and sold US$3.3m worth of stock On the 22nd of April, James Hippel exercised options to acquire 56k shares at no cost and sold these for an average price of US$58.58 per share. This trade did not impact their existing holding. Since September 2025, James' direct individual holding has increased from 129.88k shares to 142.72k. Company insiders have collectively sold US$9.2m more than they bought, via options and on-market transactions in the last 12 months. Buy Or Sell Opportunity • Apr 23
Now 27% undervalued after recent price drop Over the last 90 days, the stock has fallen 23% to US$52.20. The fair value is estimated to be US$71.47, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.2% over the last 3 years. Earnings per share has declined by 42%. For the next 3 years, revenue is forecast to grow by 6.7% per annum. Earnings are also forecast to grow by 23% per annum over the same time period. Recent Insider Transactions Derivative • Apr 19
CEO, President & Director exercised options and sold US$1.9m worth of stock On the 14th of April, Kim Kelderman exercised options to acquire 32k shares at no cost and sold these for an average price of US$58.66 per share. This trade did not impact their existing holding. For the year to June 2019, Kim's total compensation was 11% salary and 89% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since September 2025, Kim's direct individual holding has increased from 50.97k shares to 53.08k. Company insiders have collectively sold US$5.9m more than they bought, via options and on-market transactions in the last 12 months. Announcement • Apr 18
Bio-Techne Corporation Introduces Streamlined Brand Architecture With Three Portfolio Brands Bio-Techne Corporation announced a streamlined brand architecture designed to enable scientists and clinicians to more easily find the answers they need based on their application and stage of research. The company has organized its products and technologies under three focused portfolio brands -- R&D Systems™, Bio-Techne Spatial™, and Bio-Techne Diagnostics™ -- aligning its solutions with the way modern science progresses from early discovery through translational insights to clinical diagnostics. The portfolio brands will debut at the AACR Annual Meeting 2026 and AAI's IMMUNOLOGY 2026™. The R&D Systems portfolio brings together Bio-Techne's trusted proteins, antibodies, immunoassays, small molecules and innovative instruments used by scientists worldwide. R&D Systems solutions help researchers generate reproducible results, validate discoveries, and advance early-stage research towards clinical application with confidence. R&D Systems provides dependable tools needed to explore, experiment, and uncover new biological insights. R&D Systems also provides key GMP-grade reagents and tools essential for advancing cell and gene therapy workflows. The Bio-Techne Spatial portfolio leverages technologies that help researchers and clinicians translate biology and disease context across both the gold-standard RNAscope™ in situ hybridization technology and the automated COMET™ spatial hyperplex platform. Bio-Techne Spatial solutions enable scalable, high-resolution visualization of RNA and protein with multiomic analysis, delivering exceptional sensitivity and precision to reveal differences in cell structure, identify clinically relevant biomarkers, inform pathology-driven research questions and accelerate therapeutic discovery. The Bio-Techne Diagnostics portfolio provides clinical laboratories and IVD manufacturers with assay kits, IVD-grade reagents, antibodies, molecular controls, calibrators, and proficiency-testing materials needed to design, develop, and validate reliable diagnostic assays. The portfolio supports the full lifecycle of assay development from early design through deployment at scale. By delivering high-quality raw materials and comprehensive assay solutions, Bio-Techne Diagnostics helps ensure accuracy, strengthens clinical decision-making, and ultimately contributes to improved patient outcomes. Together, these three portfolios create a clearer, more connected path for customers by providing a streamlined, end-to-end view of Bio-Techne's solutions, aligning tools and technologies from discovery through translation to clinical diagnostics and accelerating scientific and clinical progress. R&D Systems™ now includes the legacy brands Novus Biologicals™, Tocris Bioscience™, and ProteinSimple™; Bio-Techne Spatial now includes the legacy brands Lunaphore™, and Advanced Cell Diagnostics™; Bio-Techne Diagnostics now includes Asuragen®, Bionostics, Cliniqa, RNA Medical®, and R&D Systems™ Clinical Controls. Announcement • Mar 25
Bio-Techne Corporation Expands Comet Solution Portfolio with Addition of Spyre Focus Panels and Spyre Amplification Kits Bio-Techne Corporation announced the expansion of its COMET solution portfolio with the addition of the new SPYRE Focus Panels and SPYRE Amplification Kits. Together, these strengthen the COMET technology modular, automated spatial biology workflow, delivering expanded flexibility, greater sensitivity, and enabling deeper, more focused interrogation of biologically meaningful data from initial assay design through final interpretation. To support these updates, new features of HORIZON Image Analysis Software have also been introduced, tailored for COMET hyperplex images using the new SPYRE tools, further streamlining tissue analysis. SPYRE Antibody Panels, including the newly introduced Stroma and Vessel Focused Panels, are modular antibody panels designed to enable flexible multiplex assay design while reducing optimization time. Panels leverage validated antibodies with ready-to-use protocols to streamline setup while maintaining flexibility to incorporate markers from a lab's own antibody library. SPYRE Amplification Kits use seqLA technology to improve the detection of low-abundance and difficult-to-detect targets. Together, SPYRE Focus Panels and SPYRE Amplification Kits strengthen Bio-Techne's commitment to deliver a fully integrated, modular, and automated spatial biology ecosystem that accelerates research and preclinical therapeutic development. These innovations continue to empower researchers to generate richer data and deeper biological understanding from every tissue sample. Buy Or Sell Opportunity • Feb 20
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 6.5% to US$57.52. The fair value is estimated to be US$72.57, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.2% over the last 3 years. Earnings per share has declined by 42%. For the next 3 years, revenue is forecast to grow by 6.8% per annum. Earnings are also forecast to grow by 24% per annum over the same time period. Announcement • Feb 16
Bio-Techne's Ella Platform Achieves Ce-Ivd Marking Expanding Access to Rapid, Cartridge-Based Immunoassays for European Clinical Laboratories Bio-Techne Corporation announced that the Ella benchtop immunoassay platform has received CE-IVD marking and is now available for sale in the European Union. This achievement brings Ella's hallmark ease of use, speed and reproducibility to clinical settings, helping laboratories streamline workflows and support timely decision-making. Ella is a compact, cartridge-based immunoassay system that delivers accurate biomarker results in under 90 minutes with minimal hands-on time. By simplifying the manual steps of traditional immunoassays, Ella reduces operator variability and provides high-quality, reproducible data suitable for both translational research and clinical applications. The platform is compatible with Simple Plex™? assays, which remain for research use only, and are powered by R&D Systems antibodies and proteins. With more than 390 analytes across neuroscience, immunology, oncology, and cell and gene therapy, the Simple Plex portfolio enables researchers to maintain consistency and data quality while working efficiently across a wide range of applications. With CE-IVD marking now in place, hospitals, clinical laboratories, or other European organizations may use Ella as a validated platform for in-house test development, clinical trials, or other translational activities. Diagnostic assay developers may also develop clinical applications on the Ella CE-IVD validated platform. The certification enhances confidence in Ella's performance and supports Bio-Techne's long-term goal to advance precision medicine by providing dependable, standardized solutions for biomarker detection. Announcement • Feb 11
Bio-Techne Corporation Announces Executive Changes, Effective March 1, 2026 Bio-Techne Corporation announced that Dr. Matt McManus, President of Bio-Techne's Diagnostics and Spatial Biology Segment, will be transitioning from his role, effective March 1, 2026, and will remain with Bio-Techne for a period of time to support a smooth transition. Steve Crouse, currently Senior Vice President of Bio-Techne's Analytical Solutions Division, has been appointed President, Diagnostics and Spatial Biology Segment, effective March 1, 2026. Steve has over two decades of experience as a senior life sciences leader at various companies. As Senior Vice President, Analytical Solutions Division, he is responsible for Bio-Techne's portfolio of protein analysis instruments and immunoassays and has driven strategic initiatives, successfully launched several innovative platforms and delivered strong growth during his four-year tenure. Before joining Bio-Techne, he most recently served as General Manager of Thermo Fisher Scientific's Protein Detection and Quantification business unit. He has an MBA from the Marshall School of Business at the University of Southern California and a M.S. in Biochemistry from Georgetown University. Price Target Changed • Feb 09
Price target increased by 7.5% to US$75.25 Up from US$70.00, the current price target is an average from 12 analysts. New target price is 13% above last closing price of US$66.78. Stock is down 4.5% over the past year. The company is forecast to post earnings per share of US$1.26 for next year compared to US$0.47 last year. Declared Dividend • Feb 06
Second quarter dividend of US$0.08 announced Dividend of US$0.08 is the same as last year. Ex-date: 13th February 2026 Payment date: 27th February 2026 Dividend yield will be 0.5%, which is higher than the industry average of 0.4%. Payout Ratios Payout ratio: 31%. Cash payout ratio: 22%. Reported Earnings • Feb 05
Second quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behind Second quarter 2026 results: EPS: US$0.24 (up from US$0.22 in 2Q 2025). Revenue: US$295.9m (flat on 2Q 2025). Net income: US$38.0m (up 8.9% from 2Q 2025). Profit margin: 13% (up from 12% in 2Q 2025). Revenue exceeded analyst estimates by 1.9%. Earnings per share (EPS) missed analyst estimates by 7.7%. Revenue is forecast to grow 6.8% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings. Announcement • Feb 04
Bio-Techne Corporation Declares Dividend for the Quarter Ended December 31, 2025, Payable on February 27, 2026 Bio-Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended December 31, 2025. The quarterly dividend will be payable February 27, 2026, to all common shareholders of record on February 16, 2026. Announcement • Feb 03
Bio-Techne Expands 3D Stem Cell and Organoid Culture Portfolio with A Fully Defined Synthetic Alternative Bio-Techne Corporation announced the launch of Cultrex™? Synthetic Hydrogel, a fully defined synthetic extracellular matrix (ECM) designed to support reproducible and scalable 3D stem cell and organoid research. The new product expands Bio-Techne's established Cultrex ECM portfolio, offering researchers a synthetic alternative that reduces lot-to-lot variability while supporting translational and regulatory-aligned research workflows alongside the Company's widely used traditional matrices. Cultrex Synthetic Hydrogel is designed to support the use of 3D organoid models across a wide range of applications, including drug screening, toxicology and personalized medicine, reducing the reliance on animal-component derived matrices and supporting the broader utilization of new approach methodologies (NAMs). By avoiding the biological variability inherent in traditional ECMs, the hydrogel helps researchers standardize experimental conditions across studies and laboratories, enabling more consistent and reliable organoid culture. Cultrex Synthetic Hydogel aligns with the FDA's broader goal of driving innovation to improve translational outcomes by offering a more reliable platform for preclinical research. With the regulatory drive for increased adoption of NAMs across the pharmaceutical industry, researchers increasingly require tools that improve the scalability, consistency, and documentation surrounding organoid workflows. The Cultrex Synthetic HydrogEL launch represents an important step toward the broader adoption of organoid models in support of translational and regulatory- aligned research. Its controlled composition supports consistency and traceability as programs advance toward regulatory-facing studies. This launch further expands Bio-Techne's robust portfolio of solutions for stem cell and organoid culture, including Cultrex Basement Membrane Extracts (BME), as well as recombinant cytokines and growth factors, AI-modified proteins, small molecules, media, and supplements. Together, these offerings provide researchers with the flexibility to select ECM solutions aligned with their experimental, scalability, and regulatory needs. Announcement • Jan 28
Bio-Techne Launches Simple Plex Ultra- Sensitive Assays on Ella Platform to Enable Femtogram-Level Detection of Neurological Biomarkers Bio-Techne Corporation announced the launch of Simple Plex Ultra-Sensitive Assays on the Ella automated benchtop platform. Early detection of neurodegenerative disease biomarkers has historically been limited by their extremely low abundance in accessible biofluids such as blood. The new, ultrasensitive assays overcome this barrier by delivering step-change improvements on the Ella platform in analytical sensitivity and reliable quantification of key biomarkers, including NFL, GFAP, pTau 217, and Amyloid b (aa1-42). This capability enables researchers to detect subtle, early biological changes that are often missed, accelerating insights into disease onset, progression, and treatment response. The assays build on Ella's proven performance, which is cited in more than 200 peer-reviewed neurology-focused publications and widely adopted in translational and clinical research, driving breakthrough diagnostic and therapeutic advances. Ella's automated workflow reduces manual steps and variability, delivering ultrasensitive assay results with an overall runtime of under three hours. These assays are intended for Research Use Only. This launch strengthens Bio-Techne's immunoassay leadership by combining ultrasensitive proteomic assays with automated instrumentation that improves reproducibility, throughput, and data quality. The Ella platform has been cited in more than 1,000 peer-reviewed publications. Bio-Techne's broad proteomic and spatial biology portfolio continues to drive breakthroughs in neuroscience research and advance precision medicine. Announcement • Dec 09
Bio-Techne Launches the Enhanced Leo System Delivering Advanced Multiplexing and High-Throughput Protein Analysis Bio-Techne Corporation announced the expanded launch and first shipment of its next-generation Leo System, powered by Simple Western Technology. The enhanced Leo System introduces dual-channel fluorescence detection alongside chemiluminescence, expanding data throughput and efficiency, and generating greater insights from precious samples. Fluorescence adds a fourth multiplexing option to its molecular weight separation, RePlex, and resampling capabilities to create even more experimental flexibility and tackle complex biological questions. This advance enables researchers to simultaneously quantify targets with distinct expression levels, assess different proteoforms, such as phosphorylated and total protein forms, in the same capillary, multiplex same-weight targets in a single run, and process up to 100 capillaries within three hours. Declared Dividend • Nov 07
First quarter dividend of US$0.08 announced Dividend of US$0.08 is the same as last year. Ex-date: 17th November 2025 Payment date: 28th November 2025 Dividend yield will be 0.6%, which is higher than the industry average of 0.4%. Payout Ratios Payout ratio: 64%. Cash payout ratio: 22%. Reported Earnings • Nov 06
First quarter 2026 earnings: EPS and revenues miss analyst expectations First quarter 2026 results: EPS: US$0.25 (up from US$0.21 in 1Q 2025). Revenue: US$286.6m (down 1.0% from 1Q 2025). Net income: US$38.2m (up 14% from 1Q 2025). Profit margin: 13% (up from 12% in 1Q 2025). Revenue missed analyst estimates by 1.6%. Earnings per share (EPS) also missed analyst estimates by 4.0%. Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings. Announcement • Nov 05
Bio-Techne Corporation Declares Dividend for the Quarter Ended September 30, 2025, Payable on November 28, 2025 Bio-Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended September 30, 2025. The quarterly dividend will be payable November 28, 2025, to all common shareholders of record on November 17, 2025. Future cash dividends will be considered by the Board of Directors on a quarterly basis. Announcement • Nov 04
Bio-Techne Corporation and Nucleai Announces the Presentation of Pivotal Data from the SECOMBIT Clinical Trial at the Society for Immunotherapy of Cancer 2025 Annual Meeting Bio-Techne Corporation and Nucleai announced the presentation of pivotal data from the SECOMBIT clinical trial at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting. The study, conducted in collaboration with Professor Paolo Ascierto, Full Professor of Oncology at the University of Napoli Federico II and Istituto Nazionale Tumori IRCCS Fondazione Pascale, showcases the significance of spatial biology in translational research by combining, for the first time, an immuno-oncology (IO) multiplex immunofluorescence (mIF) panel with advanced AI-driven multimodal biomarker analysis. Using the COMET platform and a 28-plex mIF panel, researchers profiled 42 pre-treatment biopsies from patients with metastatic melanoma. Nucleai's multimodal spatial operating system integrated high-plex imaging, histopathology, and clinical outcome data to identify distinct immune cell interactions that correlate with progression-free survival (PFS), overall survival (OS), and clinical benefit across three treatment arms incorporating Immune Checkpoint Blockade (ICB). Key Findings: Arm A (MAPKi - ICB): Immune activation markers such as PD-L1+ CD8 T-cells and ICOS+ CD4 T-cells are linked to better outcomes. Arm B (ICB - MAPKi): PD-1+ CD8 T- cells in the tumor invasive margin and their interactions with PD-L1+ CD4 T-cells correlated with improved survival. Arm C (MAPKi - IC B - MAPKi): APC-T-cell interactions in tumor margins associated with better outcomes; macrophage interactions in outer tumor microenvironment (TME) indicated poorer prognosis. The study shows that where immune cells are located and how they interact within the tumor matters significantly for treatment success. By using AI and spatial biology to map these immune niches, researchers can better predict which patients will benefit from specific therapies moving toward more personalized and effective cancer treatment. Availability at SITC 2025 Bio-Techne's full spatial biology portfolio--including the new ProximityScope™? assay and the extended SPYRE™? portfolio will be showcased at Booth #603 at SITC 2025. Visual data from the SECOMBIT study will also be presented in Poster # 528, alongside additional immuno-oncology research from Bio-Techne and its collaborators. Announcement • Oct 28
Bio-Techne Launches ProximityScope Assay on the Bond Rx Platform from Leica Biosystems to Advance Spatial Protein-Protein Interactions Research Bio-Techne Corporation announced the launch of the ProximityScope™ assay, a spatial solution developed for seamless integration with the BOND RX staining platform from Leica Biosystems. This powerful combination enables researchers to visualize functional protein-protein interactions on fixed tissue with subcellular resolution - bringing Leica's automation excellence from Leica Biosystems to the forefront of spatial biology. The ProximityScope assay provides a clear, visual signal only when two proteins of interest are physically close, revealing previously inaccessible insights into biological mechanisms. Designed to work in tandem with the BOND RX stained system from Leica Biosystems, the assay also integrates with ACD's RNAscope Multiomic LS kit, enabling enhanced detection of RNA and protein on the same tissue section. This offers scientists a uniquely powerful tool for both discovery and translational research, sparing precious tissue while delivering novel insights. Traditional methods for studying protein interactions, such as bulk pull-down assays or non-spatial proximity assays, lack localization data or require dissociation cells that lose their spatial orientation. ProximityScope addresses this gap by combining high sensitivity with high specificity and low background, providing unparalleled accuracy and confidence in results. Key applications include visualizing cell-cell interactions for studying immune checkpoints or bispecific antibodies, analyzing cell surface interactions that activate signaling pathways, evaluating antibody-based therapeutics for toxicity and target specificity, and investigating intracellular interactions involved in transcriptional activation. Announcement • Oct 15
Bio-Techne Corporation to Report Q1, 2026 Results on Nov 05, 2025 Bio-Techne Corporation announced that they will report Q1, 2026 results at 12:30 PM, US Eastern Standard Time on Nov 05, 2025 Announcement • Sep 26
Bio-Techne Advances Spatial Biology Solutions Bridging Translational Research to Clinical Applications Bio-Techne Corporation announced new advancements in its spatial biology portfolio for the RNAscope™? ISH technology and the Lunaphore COMET™?. These solutions help researchers and pathologists bridge the gap between translational research and clinical applications by enabling the detection of RNA and protein biomarkers on the same tissue section. RNAscope™? empowers pathologists and histologists to detect clinically relevant biomarkers--such as viral markers, secreted proteins, point mutations, and chromosomal translocations--within routine anatomic pathology workflows. COMET™? offers fully automated, high-throughput hyperplex analysis of both RNA and protein biomarkers, accelerating spatial multiomic workflows and enabling deeper biological insights. Scientific investigations presented this fall explore the potential of facilitating the diagnostic utility of these technologies. Studies include the use of RNAscope™? for assessing B-cell clonality with IGLL5 detection, and COMET™? for spatial profiling of lymphoid malignancies using a 21-plex seqIF™? panel. These findings demonstrate how spatial biology tools can be integrated into diagnostic workflows, especially in cases with limited tissue availability. Bio-Techne will showcase these innovations at the National Society of Histotechnology (NSH) Convention, taking place September 26-30 in Long Beach, CA. Advanced Cell Diagnostics (ACD) and Lunaphore will exhibit at booths #139 and #427, respectively. Presentations include: RNAscope™? for Routine Anatomic Pathology: Dr. Ryan Bremer will highlight the advantages of RNAscope™? over legacy RNA ISH and other methods for well-known markers and new markers of potential clinical significance, as well as the easy adoption of RNAscope into existing workflows. (Session WS29, Sep. 27, 4:45 p.m.) RNAscope™? of IGLL5 Offers New Insights in B-cell Clonality: Dr. Ishani Das has been selected for a live presentation of her poster focusing on the comparative performance of RNAscope™? for assess B-cell clonality using immunoglobulin kappa and lambda light chain markers, emphasizing the value of concurrent detection of IGLL5 only offered by RNAscope. seqIF™? Panel for Spatial Profiling of Lymphoid Malignancies: Dr. Antonio Sorrentino will present a poster showcasing the COMET technology's potential in improving the diagnosis of lymphoid malignancies, utilizing clinically validated antibodies with a 21-plex (seqIF™?) panel that integrates into the workflow of B-cell lymphomas and conserves valuable tissue from biopsies. Bio-Techne and Leica Biosystems continue to advance their partnership by co-hosting a waterfront reception at Park's Lighthouse on September 28, offering attendees a chance to network and explore RNAscope assays on Leica BOND platforms. Recent Insider Transactions Derivative • Aug 26
Independent Director notifies of intention to sell stock Roeland Nusse intends to sell 17k shares in the next 90 days after lodging an Intent To Sell Form on the 25th of August. If the sale is conducted around the recent share price of US$56.36, it would amount to US$960k. Since September 2024, Roeland's direct individual holding has increased from 43.10k shares to 44.56k. Company insiders have collectively sold US$3.0m more than they bought, via options and on-market transactions in the last 12 months. Declared Dividend • Aug 08
Fourth quarter dividend of US$0.08 announced Dividend of US$0.08 is the same as last year. Ex-date: 18th August 2025 Payment date: 29th August 2025 Dividend yield will be 0.6%, which is higher than the industry average of 0.4%. Payout Ratios Payout ratio: 38%. Cash payout ratio: 20%. Reported Earnings • Aug 06
Full year 2025 earnings: EPS misses analyst expectations Full year 2025 results: EPS: US$0.47 (down from US$1.07 in FY 2024). Revenue: US$1.22b (up 5.2% from FY 2024). Net income: US$73.4m (down 56% from FY 2024). Profit margin: 6.0% (down from 14% in FY 2024). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 52%. Revenue is forecast to grow 7.9% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has only fallen by 19% per year, which means it has not declined as severely as earnings. Announcement • Aug 06
Bio-Techne Corporation Declares Dividend for the Quarter Ended June 30, 2025, Payable on August 29, 2025 Bio-Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended June 30, 2025. The quarterly dividend will be payable August 29, 2025, to all common shareholders of record on August 18, 2025. Recent Insider Transactions Derivative • Aug 01
Executive VP of Finance & CFO exercised options and sold US$2.1m worth of stock On the 29th of July, James Hippel exercised 168.62k options at around US$44.33, then sold 147k of the shares acquired at an average of US$58.55 per share and kept the remainder. Since September 2024, James' direct individual holding has increased from 99.93k shares to 106.61k. Company insiders have collectively sold US$4.7m more than they bought, via options and on-market transactions in the last 12 months. Valuation Update With 7 Day Price Move • Jul 28
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to US$58.78, the stock trades at a forward P/E ratio of 48x. Average trailing P/E is 40x in the Life Sciences industry in the US. Total loss to shareholders of 38% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at US$61.27 per share. Major Estimate Revision • May 15
Consensus EPS estimates fall by 13% The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate fell from US$1.16 to US$1.01 per share. Revenue forecast steady at US$1.22b. Net income forecast to grow 70% next year vs 12% growth forecast for Life Sciences industry in the US. Consensus price target down from US$79.70 to US$70.11. Share price fell 3.1% to US$48.24 over the past week. Announcement • May 12
Bio-Techne Corporation to Showcase Next-Generation Solutions for Gene and Cell Therapy At American Society of Gene & Cell Therapy 2025 Bio-Techne Corporation announced it will showcase its latest spatial biology and cell and gene therapy workflow solutions at the American Society of Gene & Cell Therapy 2025 meeting taking place in New Orleans between May 13th - 17th at the New Orleans Ernest N. Memorial Convention Center. Bio-Techne will feature its cutting-edge advancements for cell and gene therapy development and manufacturing at booth 1537. Highlights include the new RNAscope protease-free workflow for visualization of biodistribution of AAV vectors, transgene mRNA, small RNAs (ASO, siRNA, miRNA) along with functional RNA and protein markers. Bio-Techne's booth will also showcase its solutions to improve cell therapy workflows, including the ProPak GMP cytokines in dose-optimized, single-use bags with weldable tubing for closed-system cell therapy manufacturing, and new AI-modified, designer proteins. The next-generation Simple Western Leo System will also be featured, with this instrument enabling the simultaneous processing of up to 100 samples in a single 3-hour run. Leading researchers along with Maithreyan Srinivasan, PhD, Chief Scientific Officer, Advanced Cell Diagnostics, a Bio-Techne brand, will present the latest innovations with RNAscope technology at ACD's symposium on May 14th at 8:30 am in room 383-385. This session will highlight NextGen RNAscope Multiomics Solutions for Spatial Precision: AAV, small RNA, CAR-T, and Beyond. Declared Dividend • May 11
Third quarter dividend of US$0.08 announced Dividend of US$0.08 is the same as last year. Ex-date: 19th May 2025 Payment date: 30th May 2025 Dividend yield will be 0.6%, which is higher than the industry average of 0.4%. Payout Ratios Payout ratio: 38%. Cash payout ratio: 23%. Price Target Changed • May 09
Price target decreased by 11% to US$71.28 Down from US$79.70, the current price target is an average from 12 analysts. New target price is 43% above last closing price of US$49.94. Stock is down 38% over the past year. The company is forecast to post earnings per share of US$1.01 for next year compared to US$1.07 last year. New Risk • May 08
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 22% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (11% net profit margin). Reported Earnings • May 07
Third quarter 2025 earnings: EPS misses analyst expectations Third quarter 2025 results: EPS: US$0.14 (down from US$0.31 in 3Q 2024). Revenue: US$316.2m (up 4.2% from 3Q 2024). Net income: US$22.6m (down 54% from 3Q 2024). Profit margin: 7.1% (down from 16% in 3Q 2024). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 57%. Revenue is forecast to grow 7.5% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 22% per year whereas the company’s share price has fallen by 17% per year. Announcement • Apr 24
Bio-Techne Announces Early Access Program for Next-Generation Spatial Protein Proximity Detection Bio-Techne Corporation announced an Early Access Program for its latest advancement in spatial biology: a powerful new assay for in situ detection of protein proximity. Built upon Advanced Cell Diagnostics RNAscope technology, this next-generation assay is designed to reveal functional interactions between proteins within intact tissues, delivering a spatial solution to explore how molecular signaling shapes disease processes - offering a truly integrated spatial multiomic view. Conventional methods for studying molecular interactions in tissues that separately measure proteins and RNA risk losing spatial fidelity, while bulk proximity assays provide no localization data. Bio-Techne's proximity detection technology addresses these gaps with a clear visual signal at subcellular resolution, built to be compatible with the RNAscope Multiomic LS workflow on BOND RX. This capability is particularly valuable for research areas where context matters -- such as assessing immune checkpoint dynamics, investigating bispecific antibodies and studying protein interactions at synaptic junctions. The Early Access Program is available to select institutions and researchers interested in incorporating spatial protein proximity capabilities into their workflows. Proof-of-concept data and case studies will be shared at the 2025 American Association for Cancer Research annual meeting, presented by Bio-Techne's scientific team. Announcement • Apr 15
Bio-Techne Corporation to Report Q3, 2025 Results on May 07, 2025 Bio-Techne Corporation announced that they will report Q3, 2025 results on May 07, 2025 Announcement • Mar 11
Bio-Techne Corporation Begins Shipping Leo - A Next Generation High-Throughput Simple Western System Bio-Techne Corporation announced that it has begun shipping the Leo™ System, powered by Simple Western™ Technology. Leo expands upon existing Simple Western platforms that offer automated protein size resolution and antibody-based protein detection by dramatically improving sample throughput and enhancing the reproducibility of protein quantitation. Leo offers the throughput and precision of standard ELISAs in a fully automated western blot assay, expanding applications in bioanalytical workflows from discovery through commercialization. Leo enables the simultaneous processing of up to 100 samples in a single 3-hour run, offering 4x the throughput of the Jess™ Simple Western System and 5x faster turn-around-times than Sally Sue™ and Peggy Sue™ Simple Western Systems. Leo also provides the experimental size, precision and reproducibility necessary for robust analytical grade protein quantitation for use in submissions to regulatory agencies. Additionally, Leo features enhanced Compass for Simple Western Software, with advanced analysis capabilities and improvements to better support 21 CFR Part 11 Compliance. Announcement • Mar 03
Bio-Techne Launches New Panel Resolving Hard-To-Decipher Carrier Screening Genes Bio-Techne Corporation announced that Asuragen, a Bio-Techne brand, has teamed up with Oxford Nanopore Technologies to launch the AmplideX®? Nanopore Carrier Plus Kit, a new genetic panel and supporting analysis software for carrier screening research. This innovative kit helps laboratories resolve genes that are challenging to analyze by conventional short-read sequencing and only partially resolved by ancillary assays. The panel is available for research use only. In 2021, the American College of Medical Genetics and Genomics (ACMG) updated its recommendations for carrier screening to include many genes that cannot be analyzed by standard short-read sequencing. In fact, half of the 10 most common genes that contribute to the risk of couples having a child with a genetic disorder are problem for short-read sequencing. Until now, laboratories have relied on multiple test technologies, including MLPA, Sanger sequencing, qPCR, long-range PCR, and others, to analyze the recommended genes. The AmplideX Nanopore Carrier Plus Kit addresses two problems for laboratories: it provides a single streamlined method, and it delivers comprehensive sequencing data compared to alternative assays. By combining novel AmplideX long-range PCR and nanopore long reads, it directly captures large genomic variants. The 11-gene panel includes the most prevalent recommended genes that cannot be detected accurately with legacy short-read sequencing methods, allowing labs to replace a patchwork testing approach with a single workflow to simplify sample-to-answer results. The kit also includes software to enable straightforward analysis without the need for advanced bioinformatics resources. Announcement • Feb 20
Bio-Techne Corporation Launches Expanded Menu of RNAscope Probes for Human and Mouse Transcriptome to Advance Spatial Biology Bio-Techne Corporation announced the launch of an expanded menu of human and mouse RNAscope™? in situ hybridization probes to advance spatial biology research and the development of next-generation therapeutics and diagnostics. Designed to deliver spatial precision with sensitivity and specificity, the Advanced Cell Diagnostics (ACD) branded RNAscope probe portfolio now includes over 70,000 unique probes across over 450 species. Representing the most referenced spatial biology technology in the industry, RNAscope provides an unprecedented single-cell view of disease pathology and therapeutic response across a wide range of diseases. Backed by the RNAscope probe guarantee, this new addition to the large and growing RNAscope probe menu enables customers to easily accelerate validation of new RNA biomarkers from single-cell genomics and spatial discovery programs. Available for purchase on bio-techne.com, customers can easily select RNAscope probes together with R&D Systems antibodies to further illuminate changes in cell phenotypes and functional states. With ready-to-use manual and automated formats available for each RNAscope probe, including for use on the automated Lunaphore COMET™? system, researchers can seamlessly advance new RNA and multiomic biomarkers from late discovery to translational research or clinical assay development using the same RNAscope probe design. Announcement • Feb 18
Bio-Techne Corporation Announces Release of GMP TcBuster Non-Viral Genome Engineering System Bio-Techne Corporation announced the official release of GMP Transposase mRNA for the TcBuster™? non-viral genome engineering system, supporting the development and manufacture of immune cell- and stem cell-based therapies. The TcBuster System has been widely used by researchers to introduce large cargo genetic modifications in a range of cell types. The new GMP transposase will offer a clearer path to clinic for applications in gene editing cell therapies, such as CAR-T or TCR generation. Non-viral TcBuster offers numerous benefits over traditional lentivirus-based engineering methods for cell therapy development. The natural transposase has been enhanced through protein engineering, resulting in a hyperactive enzyme. As a result, multiple genes can be delivered from a GMP transposon simultaneously while maintaining high editing efficiency and a de-risked insertional profile. By negating the need for viral clearance methods, the TcBuster system also significantly reduces both the time to market and cost requirements for cell therapy developers. Moreover, Bio-Techne has a strong and reliable supply chain for both RUO & GMP grade reagents, including innovative options for closed-system manufacturing, making it a dependable option for scaling from research to clinical and commercial stages. The TcBuster system is compatible with a range of cell types, including immune cells and stem cells, and can be used for a wide range of applications, including autologous CAR-T or TCR manufacturing, allogeneic NK therapies, and for engineering bioprocessing cell lines for therapeutic biologics production. Declared Dividend • Feb 07
Second quarter dividend of US$0.08 announced Dividend of US$0.08 is the same as last year. Ex-date: 14th February 2025 Payment date: 28th February 2025 Dividend yield will be 0.4%, which is about the same as the industry average. Payout Ratios Payout ratio: 32%. Cash payout ratio: 20%. Reported Earnings • Feb 05
Second quarter 2025 earnings: EPS and revenues exceed analyst expectations Second quarter 2025 results: EPS: US$0.22 (up from US$0.17 in 2Q 2024). Revenue: US$297.0m (up 9.0% from 2Q 2024). Net income: US$34.9m (up 27% from 2Q 2024). Profit margin: 12% (up from 10% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 4.1%. Earnings per share (EPS) also surpassed analyst estimates by 1.9%. Revenue is forecast to grow 9.1% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 14% per year whereas the company’s share price has fallen by 11% per year. Announcement • Feb 05
Bio-Techne Corporation Declares Dividend for the Quarter Ended December 31, 2024, Payable on February 28, 2025 Bio-Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended December 31, 2024. The quarterly dividend will be payable February 28, 2025, to all common shareholders of record on February 17, 2025. Future cash dividends will be considered by the Board of Directors on a quarterly basis. Announcement • Feb 04
Bio-Techne Appoints Amy E. Herr to Board of Directors Bio-Techne Corporation announced the appointment of Amy E. Herr, Ph.D. to serve as an independent director on the Company's Board of Directors beginning on February 1, 2025. Dr. Herr will serve on the Science & Technology Committee of the Board of Directors. Dr. Herr is a Chancellor's Professor of Bioengineering at the University of California, Berkeley. Dr. Herr also currently serves as the Vice President of the Chan Zuckerberg Biohub Network, a group of nonprofit research institutes established to create tools required to understand the mysteries of the cell to ultimately cure, prevent, and manage human disease. Since joining the faculty at UC Berkeley in 2007, Dr. Herr has served in several university, national, and international leadership roles including as the Founding Executive Director of UC Berkeley's Bakar BioEnginuity Hub – an incubator for academic spin-out companies, and on the National Advisory Council for Biomedical Imaging and Bioengineering (NACBIB) for the National Institutes of Health, as well as governmental science advisory boards. Dr. Herr was a co-founder and advisory board member of Zephyrus Biosciences, which was acquired by Bio-Techne in 2016. Dr. Herr holds a Doctor of Philosophy in Mechanical Engineering from Stanford University and a Bachelor of Science in Engineering & Applied Science from Caltech. Dr. Herr's appointment completes a two-year process by the Board of Directors to identify and appoint successors to retiring directors Randy Steer, who retired in 2024, and Dr. Roeland Nusse, who will be retiring later in 2025. Dr. Herr will succeed Dr. Roeland Nusse. Recent Insider Transactions Derivative • Jan 28
CEO, President & Director notifies of intention to sell stock Kim Kelderman intends to sell 13k shares in the next 90 days after lodging an Intent To Sell Form on the 27th of January. If the sale is conducted around the recent share price of US$77.05, it would amount to US$1.0m. For the year to June 2018, Kim's total compensation was 11% salary and 89% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since September 2024, Kim's direct individual holding has decreased from 39.94k shares to 39.00k. Company insiders have collectively sold US$4.7m more than they bought, via options and on-market transactions in the last 12 months. Announcement • Jan 11
Bio-Techne Expands R&D Systems Ai-Engineered Designer Protein Portfolio to Advance Cell Therapy and Regenerative Medicine Bio-Techne announced the launch of new designer proteins engineered using advanced Artificial Intelligence (AI) based design platforms and protein evolutionary workflows. This expanded portfolio from Bio-Techne's R&D Systems brand includes IL-2 Heat Stable Agonist, Activin A Hyperactive, FGF basic Heat Stable (available both for research use only (RUO) and made under good manufacturing processes (GMP) for therapeutic development), as well as Wnt/RSPO1 Agonist, Wnt/RSPO2 Agonist, and Wnt/RSPO3 Agonist proteins. These innovative recombinant proteins are designed and engineered to address critical needs in cellular therapy workflows and research applications, including improved cell culture performance and optimized cell expansion. Leveraging generative AI trained on data developed over almost five decades of proteomic leadership, protein library evolution, and rational design, Bio-Techne's expanded portfolio delivers next-generation cytokines and growth factors with tailored functionalities such as hyperactivity, enhanced receptor affinities, and improved heat stability. The new products include: IL-2 Heat StableAgonist: Engineered with enhanced thermal stability and altered receptor affinity for improved biological activity, ideal for cellular therapy applications such as CAR T-cell or Tumor-infiltrating lymphocytes (TIL) expansion. Activin A Hyperactive: Optimized for superior performance in regenerative medicine cell differentiation applications. FGF basic Heat Stable: A robust and versatile growth factor designed for improved protein stability and performance for stem cell culture applications, available in both RUO and GMP formats to support cell therapy manufacturing and advanced research. Wnt/RSPO 1, Wnt/RSPo2, and Wnt/R SPO3 Agonists: Key reagents for advancing stem cell research, organoid development, and regenerative medicine. With this expanded portfolio, Bio-Techne continues to lead the way in delivering disruptive innovations to the life sciences and therapeutic development communities. Bio-Techne designer proteins are available as part of market leading R&D Systems branded portfolio of proteins. 
